Article Text

Download PDFPDF
Antipsychotics, cognitive decline and death in Alzheimer’s disease: the London and South-East Region Alzheimer’s Disease longitudinal study
  1. D Ames
  1. Correspondence to:
 D Ames
 Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, Normanby House, St George’s Hospital, 283 Cotham Rd, Kew, Victoria 3101, Australia; dames{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The LASER-AD study provides limited reassurance in relation to the occasional prescription of novel antipsychotics to elderly people with dementia

For psychiatrists in the business of helping old people who exhibit delusions and challenging behaviours related to dementia, it will be a relief to read some good news at last. Apparently, even if we may not be helping old people with dementia very much when we treat them with an atypical antipsychotic,1 we may after all not be hastening their deaths or irreversibly …

View Full Text


  • Competing interests: DA has received research support, assistance to attend conferences, and honoraria for lectures and consultancy services from companies which market antipsychotic drugs, including Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Janssen Cilag, Novartis and Pfizer.

Linked Articles